Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment

  Measured over: Cycle 1 (28 days)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs)

  Measured over: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

• Number of Participants With Treatment-emergent Laboratory Abnormalities

  Measured over: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

• Number of Participants With Clinically Significant Vital Signs Values

  Measured over: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

• Maximum Percentage Change From Baseline in Weight

  Measured over: From Baseline (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

• Number of Participants With Any Dose Modifications

  Measured over: From first dose of the study treatment (Day 1) up to the last dose of study treatment (maximum treatment duration up to 19.8 months)

Changes Tremor has spotted